Report cover image

Global Interferons market - 2024-2031

Publisher DataM Intelligence 4Market Research LLP
Published Jul 10, 2024
Length 186 Pages
SKU # DTAM18976655

Description

Global Interferons market - 2024-2031


Global Interferons Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Interferons are proteins produced and released by host cells against pathogenic microbes like bacteria, viruses, fungi, and tumor cells. They belong to the cytokines class and are considered the first line of defense against microbial infections.

Interferons are currently used clinically to treat viral infections such as hepatitis C, cancers including non-Hodgkin’s lymphoma, and autoimmune diseases such as multiple sclerosis. This activity outlines the different types of interferons, namely interferon alpha, beta, and gamma.

Market Dynamics: Drivers & Restraints

Rise in prevalence of chronic diseases

The rise in the prevalence of chronic diseases is a significant driver of the Interferons market. Chronic diseases like cancer, multiple sclerosis, and hepatitis are increasing in prevalence, increasing the demand for interferon therapy as part of treatment regimens.

For instance, according to WHO, globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year. WHO estimated that in 2022, approximately 2,42,000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

High cost of treatment

Interferon development is expensive due to its complexity and complex manufacturing processes. Unlike small molecules, which are chemically synthesized, interferons require significant capital investment and high operating costs. Manufacturers must submit more data for pre-clinical and clinical studies, making registration time-consuming and restraining market growth.

For instance, The total cost of the IFN treatment regimen was estimated to range between US$1,120 and US$1,962. The total cost of the Peg-IFN treatment regimen was between US$2,156 and US$5,887.

Segment Analysis

The global interferons market is segmented based on product type, application, end-user and region.

The inteferon alpha from the product type segment accounted for approximately 43.3% of the interferons market share

The inteferon alpha from the product type segment accounted for approximately 43.3%. Alpha interferon is a cytokine produced by the innate immune system in response to environmental exposures including viral infections. Alpha interferon in various formulations has been developed as therapy of several forms of cancer and viral infections, but its major use has been as therapy of chronic hepatitis C.

For isntance, in April 2022, Northwestern Medicine researchers have discovered a new signaling pathway that inhibits the anti-tumor response of interferons in patients with a specific type of blood cancer, as reported in Nature Communications. Interferon therapy, namely interferon-alpha, has previously been proven to be effective in treating myeloproliferative neoplasms, a type of blood cancer in which patients have mutations in their bone marrow’s stem cells.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the high burden of cancer coupled with developed medical and healthcare establishments and the availability of products in the region. Also, novel product launches, FDA approvals help the region to grow during the forecast period.

For instance, in September 2023, Heligenics, Inc. a pioneering biotechnology company applying functional genomics to drug discovery, announced that it has reshaped the landscape of interferon beta drugs (IFN) which are widely-prescribed for Multiple Sclerosis.

Covid 19 Impact Analysis

The interferon market is expected to grow due to the COVID-19 pandemic, as there are no reliable treatments or vaccinations. Researchers are screening compound libraries for existing drugs with antiviral effects on COVID-19 and developing new drugs targeting SARS-CoV-2 or host factors. Trials are being conducted to create viable drug candidates for effective COVID-19 treatment. The University of Southampton and Synairgen Research Ltd. are currently testing SNG001, an inhalation formulation of interferon-beta-1a, for people with chronic obstructive pulmonary disease (COPD).

Market Segmentation

By Product Type
• Inteferon Alpha
• Inteferon Beta
• Inteferon Gamma

By Application
• Hepatitis B
• Hepatitis C
• Melanoma
• Leukemia
• Multiple Sclerosis
• Renal Cell Carcinoma
• Others

By End User
• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Zydus Cadila, Merck & Co., Inc., Bristol-Myers Squibb, Novartis AG, Schering-Plough Corporation, Roche, Biogen Inc., Bayer AG, Biosidus, Amega Biotech among others

Key Developments

In May 2024, researchers from Johns Hopkins Medicine uncovered insights as to why lupus symptoms and severity present differently in individuals with the autoimmune condition, which affects up to 1.5 million Americans. The team says this is a crucial step forward in understanding the biological mechanisms behind lupus and may also lead to shifts in how clinicians treat patients with the condition.

Why Purchase the Report?
• To visualize the global interferons market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the interferons market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global interferons market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

186 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of chronic diseases
4.1.1.2. Rise of advancements in drug delivery
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Inteferon Alpha *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Inteferon Beta
7.4. Inteferon Gamma
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Hepatitis B*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hepatitis C
8.4. Melanoma
8.5. Leukemia
8.6. Multiple Sclerosis
8.7. Renal Cell Carcinoma
8.8. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Research and Diagnostic Laboratories
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Zydus Cadila*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Merck & Co., Inc
12.3. Bristol-Myers Squibb
12.4. Novartis AG
12.5. Schering-Plough Corporation
12.6. Roche
12.7. Biogen Inc
12.8. Bayer AG
12.9. Biosidus
12.10. Amega Biotech
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us